Ocular Assessments in Patients Treated With Tivdak®
Phase 4
100
about 3.6 years
18+
Female only
77 sites in FL, GA, IL +14
What this study is about
This trial is testing possible eye side effects of TIVDAK, a medication used to treat recurrent or metastatic cervical cancer. It involves regular eye exams for participants who have not received TIVDAK before and do not currently have any eye problems. Participants will receive TIVDAK every 3 weeks as an infusion until it is no longer effective against their cancer.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take TIVDAK
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
intravenous
Primary: Type, incidence and severity of ocular adverse events (AEs)
Secondary: AEs leading to dose modifications including treatment discontinuation, Incidence of serious adverse events (SAEs), Time to onset of ocular AEs, Time to resolution of ocular AEs
Oncology